What it does
Advanced Material Development (AMD) is a private company that invests in and develops applications based on its proprietary nanomaterial platform technologies.
The company is developing intellectual property by funding and advising material science university research groups, while also collaborating with government and business partners to solve challenges in industries such as defence, aerospace, automotive, retail, RFID, printed electronics, chemicals and pharmaceuticals.
AMD is currently collaborating with the University of Texas at Austin in the US, and the universities of Sussex and Surrey in the UK, which have teams currently working on Conductively Optimized Graphite (COG) nano-material and other technologies.
The company aims to present its IP to market through a variety of profitable commercial arrangements, with its patent protected liquid processing technology underpinning the development of a variety of applications in key areas including sensors, flexible electronics, functional coatings, security (including anti-counterfeiting) and structural health monitoring.
Graphene’s low cost of production, high performance and environmental sustainability make it a potentially important material for use in electronic devices.
Pharmaceutical nanotechnology is a newer area for the group but has enjoyed an explosion of interest in 2020, including in the company’s research into a new treatment system that aims to deliver drugs directly into the lungs of people suffering from COVID-19 and other respiratory diseases.
How it is doing
In March, AMD moved up a gear when it brought in IP heavy-hitter Dr Anthony Thomson as chief executive of Life Science subsidiary CoM3D.
Thomson, who will also advise on IP commercialisation and join AMD’s advisory panel, has held numerous roles in the technology, automotive, health, capital markets and university sectors, most recently managing an exit to US giant Qualcomm.
This was followed in April by another high-level appointment when Dr Izabela Jurewicz, a teaching fellow in soft matter science at the University of Surrey and principal investigator of AMD’s work at the university, joined the company’s advisory panel.
Jurewicz is also a former researcher for AMD’s chief scientific advisor, Professor Alan Dalton, and maintains close links with his team at the University of Sussex.
Meanwhile, the company’s partnership with the University of Texas at Austin is focused on pharmaceutical nanotechnology and seeks to develop methods to make drugs more soluble and usable.
The collaboration, which is formalised through CoM3D, involves new ways of producing and delivering drugs to patients, including via 3D printing personalised medicines.
AMD has so far led a funding round for two projects, one of which expands into the current fight against viral pathogens like coronavirus.
The coronavirus project involves the development of a treatment system that aims to deliver drugs directly into the lungs of patients suffering from the disease.
Compared with existing methods of producing nanoparticles for drugs, such as emulsion evaporation, CoM3D said advanced 3D printing technology can produce specific sized designed particles needed for drug delivery “in a faster more efficient process, suitable for treatment and vaccination against future seasonal and novel respiratory viruses”.
More recently in May, the company also revealed that it is holding talks with potential partners in the RFID antenna industry as progress continues to be made in developing its COG nano-material.
September saw AMD brought in by QinetiQ to join its WSRF research contract with the UK’s Defence Science and Technology Laboratory.
- Developments in talks with potential RFID antenna partners
- Possible treatment system for coronavirus
- Other uses of graphite for other sectors